Business Context and Reporting Period
This Form 8-K is filed by Ocuphire Pharma, Inc. (not Opus Genetics, Inc., as indicated in the metadata) on March 10, 2021. The report announces the financial results for the fiscal year ended December 31, 2020. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol OCUP.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the text provided. It serves primarily as a notification that the annual results have been issued.
Guidance, Outlook, and Risks
The text does not contain specific guidance, outlook, management commentary, or risk factors. It notes that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liability of that section.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the attached Press Release (Exhibit 99.1).
- Confirm the discrepancy between the metadata company name ("Opus Genetics, Inc.") and the actual registrant ("Ocuphire Pharma, Inc.").
- Review the full press release for any forward-looking statements or operational updates not summarized in this 8-K.
- Check the company's status as an emerging growth company, as indicated by the checkmark in the filing.